Document Detail


Absence of effects of ketanserin on renal prostacyclin and thromboxane A2 in essential hypertension.
MedLine Citation:
PMID:  2065689     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The anti-hypertensive effect of ketanserin, a new antagonist of 5-HT2-serotonergic receptors, was evaluated in 10 patients with uncomplicated essential hypertension. At the end of 2 weeks of placebo wash-out and following 2 and 4 weeks of treatment with ketanserin (20 mg twice daily), blood pressure and heart rate were measured both in the supine and standing position. In addition, before and at the end of treatment, plasma renin activity (PRA), plasma concentration of aldosterone and the nocturnal urinary excretion of 6-keto-PGF1 alpha and TXB2, the two metabolites that largely reflect the renal synthesis of prostacyclin and thromboxane, respectively, were determined. The study was carried out in a metabolic ward where the intake of sodium was adjusted to 100-120 mmol day-1. Ketanserin significantly reduced blood pressure both in the supine and standing position with no significant change of heart rate. The treatment did not produce any variation of PRA, aldosterone, urinary excretion of 6-keto-PGF1 alpha or TXB2. These results indicate that ketanserin reduces blood pressure without interfering with the renin-angiotensin-aldosterone system or the renal synthesis of prostacyclin and thromboxane.
Authors:
G Gambini; S Rossi; C Valori
Related Documents :
3330989 - Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume,...
6116609 - Antihypertensive effect of e-643, a new alpha-adrenergic blocking agent.
6999899 - Normotensive primary aldosteronism.
1837009 - The influence of right heart catheterisation on pulmonary arterial pressure in chronic ...
8448909 - Acute adrenal crisis complicating hypertensive congenital adrenal hyperplasia due to 11...
8420299 - Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in conges...
8174529 - The effects of dopamine and noradrenaline on cardiovascular function in patients with a...
16398669 - Cardiovascular responses induced during high-intensity eccentric and concentric isokine...
362359 - Effects of continuous positive airway pressure after oleic acid-induced lung injury in ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European heart journal     Volume:  12     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1991 Apr 
Date Detail:
Created Date:  1991-08-09     Completed Date:  1991-08-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  550-3     Citation Subset:  IM    
Affiliation:
Instituto di Patologia Speciale Medica e Metodologia Clinica, Università di Perugia, Terni, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Ketoprostaglandin F1 alpha / urine
Adult
Aged
Epoprostenol / biosynthesis*
Female
Humans
Hypertension / drug therapy*,  metabolism,  physiopathology
Ketanserin / pharmacology*
Kidney / drug effects*,  metabolism
Male
Middle Aged
Renin-Angiotensin System / drug effects
Thromboxane A2 / biosynthesis*
Thromboxane B2 / urine
Chemical
Reg. No./Substance:
35121-78-9/Epoprostenol; 54397-85-2/Thromboxane B2; 57576-52-0/Thromboxane A2; 58962-34-8/6-Ketoprostaglandin F1 alpha; 74050-98-9/Ketanserin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Piroximone, dobutamine and nitroprusside: comparative effects on haemodynamics in patients with cong...
Next Document:  Response of recurrent giant cell myocarditis in a transplanted heart to intensive immunosuppression.